Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Michel L., de Meijer, Claudine, Wyndaele, Dirk, Noordzij, Walter, Leliveld-Kors, Annemarie M., van den Bosch, Joan, van den Berg, Pieter H., Baka, Agni, Gaultney, Jennifer G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797195/
https://www.ncbi.nlm.nih.gov/pubmed/28866822
http://dx.doi.org/10.1007/s40258-017-0350-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797195/
https://www.ncbi.nlm.nih.gov/pubmed/28866822
http://dx.doi.org/10.1007/s40258-017-0350-x

Ejemplares similares